{"id":135314,"date":"2022-11-01T07:58:31","date_gmt":"2022-11-01T11:58:31","guid":{"rendered":"https:\/\/44.250.171.167\/?p=135314"},"modified":"2022-11-03T11:45:38","modified_gmt":"2022-11-03T15:45:38","slug":"jubilant-ingrevia-ltd-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Jubilant Ingrevia Ltd Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<span class=\"embed-youtube\" style=\"text-align:center; display: block;\"><iframe loading=\"lazy\" class=\"youtube-player\" width=\"640\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/zEZQ7mQGxGM?version=3&#038;rel=1&#038;showsearch=0&#038;showinfo=0&#038;iv_load_policy=1&#038;fs=1&#038;hl=en-US&#038;autohide=2&#038;wmode=transparent\" allowfullscreen=\"true\" style=\"border:0;\" sandbox=\"allow-scripts allow-same-origin allow-popups allow-presentation allow-popups-to-escape-sandbox\"><\/iframe><\/span>\n<p><strong>Key highlights from Jubilant Ingrevia Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/JUBLINGREA\/\">JUBLINGREA<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>[00:10:34] JUBLINGREA expects its 2H23 performance to be better than 1H23, assuming no unexpected adverse events.<\/li>\n<\/ul>\n<ul>\n<li>[00:11:06] JUBLINGREA continues the efforts towards improving its revenue mix of Specialty and Nutrition segment to 65% by FY27 from 46% in FY22. Additionally, this is expected to be a key driver for overall margin improvements.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:16:34] Tarang Agrawal from Old Bridge asked that for the chemical intermediates business if there was any inventory loss in 1H23. Rajesh Srivastava MD replied that acetic acid prices at 1Q23 end was $745, and 2Q23 ended with $620. So there was a reduction of $120 which makes the company\u2019s 20 days stock valuation reduction on a gradual basis.<\/li>\n<\/ul>\n<ul>\n<li>[00:17:18] Tarang Agrawal from Old Bridge enquired about the volume growth on the specialties chemicals business for 2Q23. Rajesh Srivastava MD replied that the company has growth volume. More than 65% of the entire growth of Specialty Chemicals is contributed by volume growth.<\/li>\n<\/ul>\n<ul>\n<li>[00:27:24] Pratik Kothari from Unique Portfolio Managers enquired about the volume numbers for health and nutrition and intermediate. Rajesh Srivastava MD answered that on Health &amp; Nutrition, Niacinamide volume has de-grown by 40% over last year. On Chemical Intermediates, volumes have grown by almost 10-12%.<\/li>\n<\/ul>\n<ul>\n<li>[00:28:54] Pratik Kothari from Unique Portfolio asked about other expenses increasing to INR300 crores. Prakash Chandra Bisht CFO replied that the SEBI format for other expenses is not all fixed expenses. The expenses have gone up primarily on account of freight and also increase in tolling business.<\/li>\n<\/ul>\n<ul>\n<li>[00:31:43] \u00a0Rohan Gupta of Nuvama asked about the development update of Diketene and CDMO projects. Rajesh Srivastava MD answered that Diketene plant has come out successfully both on capacity, cost and quality. Currently utilization is 40-50% and the company is confident of touching 80-100% capacity in 4Q23 for Diketene.<\/li>\n<\/ul>\n<ul>\n<li>[00:33:09] Rohan Gupta of Nuvama asked that with a 40-50% utilization in Diketene, if the company is completely dependent on domestic market consumption. Rajesh Srivastava MD answered that the company has already started export market with great success. However, for now the major volumes are domestic.<\/li>\n<\/ul>\n<ul>\n<li>[00:34:25] Rohan Gupta with Nuvama asked about the drivers of strong volume growth in Specialty Chemicals. Rajesh Srivastava MD replied that in Specialty Chemicals, major business is pyridine and pyridine derivatives, except for the Diketene and CDMO business. So the growth is primarily from pyridine and pyridine derivatives.<\/li>\n<\/ul>\n<ul>\n<li>[00:37:57] Nitesh Dhoot from Prabhudas Lilladher enquired that on the Chemical Intermediates segment, if the spreads normalized for ethyl acetate and acetic anhydride. Rajesh Srivastava MD said that on anhydride per kg realization is improving. So as volumes increase, overall profitability of chemical intermediates business will improve.<\/li>\n<\/ul>\n<ul>\n<li>[00:39:03] Nitesh Dhoot from Prabhudas Lilladher queried about the capacity utilization for anhydride and ethyl acetate. Rajesh Srivastava MD said that on anhydride, the company is in a range of 70-80% overall. However, in the next couple of quarters the utilization is going to significantly improve looking at volumes.<\/li>\n<\/ul>\n<ul>\n<li>[00:41:24] Nitesh Dhoot of Prabhudas Lilladher asked about increased net debt levels and when it\u2019s going to peak looking at the capex the company has. Rajesh Srivastava MD answered that the increase is very short term due to profitability being lower and capex being strong. However, H2 performance is expected to improve significantly.<\/li>\n<\/ul>\n<ul>\n<li>[00:53:02] Rohit Sinha with Sunidhi Securities asked about the region of maximum traction for acetic anhydride volumes growth and sustainability of it. Rajesh Srivastava MD replied that the increase is across the region.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q2 FY23 Earnings Concall Management Update: [00:10:34] JUBLINGREA expects its 2H23 performance to be better than 1H23, assuming no unexpected adverse events. [00:11:06] JUBLINGREA continues the efforts towards improving its revenue mix of Specialty and Nutrition segment to 65% by FY27 from 46% in FY22. Additionally, this is [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Jubilant Ingrevia Ltd Q2 FY23 Earnings Conference Call Insights #JUBLINGREA #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5753],"tags":[8519,10169,9019],"class_list":["post-135314","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-industrials","tag-chemicals","tag-earnings","tag-specialty-chemicals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143010,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-jubilant-ingrevia-limited-for-q3-fy23\/","url_meta":{"origin":135314,"position":0},"title":"Earnings Summary Of Jubilant Ingrevia Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 28, 2023","format":false,"excerpt":"Jubilant Ingrevia Limited (NSE: JUBLINGREA) is an integrated pharmaceutical and life sciences company headquartered in Noida, India. The company operates in the specialty chemicals, life sciences, and pharma segments. Jubilant Ingrevia has manufacturing facilities in India and North America and a global sales network covering over 100 countries. The company's\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":129589,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":135314,"position":1},"title":"Jubilant Ingrevia Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/q-jII_ukXcc Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q4 FY22 Earnings Concall Management Update: JUBLINGREA said it recorded the highest ever revenue of INR4,949 crore and highest ever EBITDA of INR863 crore in FY22, which is a growth of 42% and 38%, respectively over FY21. JUBLINGREA also commented that estimated\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127005,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":135314,"position":2},"title":"Jubilant Ingrevia Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 2, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=VEV5IjVrTNI Key highlights from Jubilant Ingrevia Ltd (JUBLINGREA) Q3 FY22 Earnings Concall Management Update: JUBLINGREA commented that with its capex plans shaping up, it is on course of doubling the revenue by FY26 from the base of FY21. For FY23 capex is expected to be around INR300 crore. Q&A Highlights:\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":156180,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q2fy24-32-fall-in-profits\/","url_meta":{"origin":135314,"position":3},"title":"Jubilant Ingrevia Ltd Q2FY24; 32% fall in Profits","author":"Hardik Bhandare","date":"November 14, 2023","format":false,"excerpt":"Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Financial Results: Jubilant Ingrevia Ltd reported Revenues for Q2FY24 of \u20b91,020.00 Crores down from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-174.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166645,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q3fy25-77-rise-in-profits\/","url_meta":{"origin":135314,"position":4},"title":"Jubilant Ingrevia Ltd Q3FY25; 77% rise in Profits","author":"Chirag Gupta","date":"February 4, 2025","format":false,"excerpt":"Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Financial Results: Jubilant Ingrevia Ltd reported Revenues for Q3FY25 of \u20b91,057.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168642,"url":"https:\/\/alphastreet.com\/india\/jubilant-ingrevia-ltd-q4fy25-155-rise-in-profits\/","url_meta":{"origin":135314,"position":5},"title":"Jubilant Ingrevia Ltd Q4FY25; 155% rise in Profits","author":"Chirag Gupta","date":"June 4, 2025","format":false,"excerpt":"Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards. Financial Results: Jubilant Ingrevia Ltd reported Revenues for Q4FY25 of \u20b91,051.00 Crores down from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/1-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=135314"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/135314\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=135314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=135314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=135314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}